In addition, most recent progress on inhibitors of IL-6 or its receptors, tocilizumab, sarilumab, siltuximab and olokizumab, is also summarized from perspective of clinical trials for COVID-19 therapy. The gene discussed is IL6; the disease is COVID-19.